BioNTech has entered the ADC field with an exclusive license and collaboration agreement with China’s DualityBio Ltd for two antibody-drug conjugate (ADC) assets.
ADVERTISEMENT
ADVERTISEMENT
Log in here to read the desired article.
ADVERTISEMENT
BioNTech has entered the ADC field with an exclusive license and collaboration agreement with China’s DualityBio Ltd for two antibody-drug conjugate (ADC) assets.

